ESR1 and breast carcinoma: However, the results from the CALGB 40302 (Alliance) trial demonstrated that addition of lapatinib to fulvestrant did not improve progression free survival (PFS) or overall survival (OS) in advanced ER+/HER2− breast cancer [33].